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Abstract: Amisulpride is an atypical antipsychotic drug with a unique receptor pharmacology 
which is dose dependent. It is a standard treatment in dysthymia as well as in psychosis. 
Amisulpride is efficacious, effective and well tolerated in positive symptoms of schizophrenia: 
there is extensive evidence that it treats negative symptoms when given in low doses, although 
relative lack of EPS and an antidepressant effect may contribute. In first-episode patients ami-
sulpride is an option, although there is little comparative work available. Amisulpride has the 
best evidence as an effective adjunct to clozapine treatment. Regarding intellectual function, 
amisulpride appears cognitive sparing but the clinical relevance of this remains obscure. There is 
evidence that amisulpride can improve social function but again there is little comparative work 
to demonstrate any particular advantages. Regarding the current conventional versus atypical 
antipsychotic controversy, amisulpride did better in switching studies and meta-analyses than in 
the single large pragmatic randomized trial reported to date. It is a versatile drug, and may offer 
advantages over other atypical antipsychotic drugs in the treatment of negative and depressive 
symptoms, and tolerability advantages such as the avoidance of weight gain. Essentially it rests 
with the treating clinician to employ a rational psychopharmacological approach towards the 
individual patient: there will be few circumstances in which amisulpride will not be a likely 
contender as a treatment choice.
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Introduction
Amisulpride is an atypical antipsychotic drug: it is one of the class of atypical antipsy-
chotic drugs indicated for the treatment of schizophrenia. Amisulpride is a benzamide 
drug, with both antipsychotic and antidepressant properties. It is very similar to sulpir-
ide, which was introduced previously: amisulpride has been much more extensively 
marketed than sulpiride in recent years.
Amisulpride was first licensed in France in 1986, but was not available in the 
UK until 1998. It is not licensed in the US. Given the introduction of several other 
atypical antipsychotic drugs over the last 10 years, and the ongoing controversy about 
their efficacy and tolerability compared to conventional antipsychotic drugs, a review 
of amisulpride seems timely. This review concentrates on symptomatic efficacy in 
schizophrenia across syndromal domains.
Neuroscience and pharmacology
The affinity profile of amisulpride (and sulpiride) is unique amongst both conventional 
and atypical antipsychotic drugs. In vitro, amisulpride selectively binds to D2 and Neuropsychiatric Disease and Treatment 2009:5 268
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D3 dopamine receptors, but with preference for the latter. 
Unlike the other drugs in the atypical antipsychotic class, 
amisulpride is devoid of any affinity for serotonergic, alpha-
adrenergic, histaminergic or muscarinic receptors. Another 
difference between amisulpride and alternative atypical 
antipsychotic drugs is that it binds to surface receptors 
only, not intracytoplasmic receptors as well.1 The clinical 
relevance of this is not entirely clear.
The reformulated dopamine hypothesis of schizophrenia 
has postulated that overactivity of dopaminergic neurones 
in limbic areas of the brain is responsible for positive 
symptoms, while dopaminergic under-activity in the frontal 
cortex results in negative symptoms and cognitive impair-
ment.2 While D2 receptors are widely distributed through 
the brain, D3 receptors are concentrated in limbic and 
cortical areas, which have been repeatedly implicated in 
schizophrenia pathophysiology. This may give amisulpride 
advantages in that it is more closely targeted to the relevant 
neurotransmitter systems than alternative antipsychotic 
drugs. Moreover a relative lack of nigrostriatal binding 
could reduce the problem of extrapyramidal side effects. 
Furthermore, amisulpride has preferential affinity for 
presynaptic autoreceptors, as opposed to the affinity for 
postsynaptic receptors which predominates the action of 
other antipsychotic drugs. In rats, low doses of amisulpride 
preferentially increase dopaminergic transmission in the 
mesolimbic system.3
It was therefore predicted that amisulpride would alleviate 
both the proposed dopaminergic underactivity in the frontal 
cortex, and the overactivity in the limbic system, which 
characterize schizophrenia pathophysiology, without the 
inevitable induction of extrapyramidal side effects.
This unique pharmacology is largely consistent 
with the therapeutic profile of amisulpride: it has been 
shown to control both positive and negative symptoms of 
schizophrenia, and is reasonably well tolerated by virtue 
of its lack of other significant affinities. For instance 
amisulpride has a low propensity to cause catalepsy in 
rats,4 and a low incidence of extrapyramidal side effects 
in clinical studies. However, failure to induce catalepsy 
may be species specific.5
Even so, neuroimaging in humans has demonstrated 
reasonable separation between dosages associated with 
therapeutic as opposed to extrapyramidal side effects.6 Later 
work has reported two distinct binding profiles according to 
dose: striatal binding is only present at high dosage, at low 
dosage extrastriatal binding alone was observed7 validating 
reports of low dose efficacy for negative symptoms. However 
there are other reports to the effect that amisulpride and 
risperidone demonstrate very similar D2/D3 binding in limbic 
and striatal areas, in both patients and healthy volunteers.8 
More work9 confirmed that amisulpride does bind to D2 
receptors and this is dose dependent.
On the other hand, amisulpride’s unusual affinity for 
presynaptic dopaminergic autoreceptors may explain its 
efficacy for negative symptoms at low doses10 and is efficacy 
in dysthymia and in chronic mild depression.11 Moreover, the 
fast dissociation hypothesis may contribute to the explanation 
of the atypical clinical profile of amisulpride.12
Healthy volunteer studies suggest little pharmacokinetic 
differences between young and elderly subjects.13 In humans, 
a dose ranging study established the optimum dose of amisul-
pride in acute schizophrenic relapse as 400 to 800 mg.14 There 
was no increase in extrapyramidal side effects, apparently, 
between a low dose of 100 mg daily and 1200 mg. However, 
amisulpride is prone to inducing neuroendocrine side effects 
such as hyperprolactinemia, perhaps to a greater degree than 
conventional antipsychotic drugs.15,16
Unusually, amisulpride is not extensively metabolized, 
but cleared by renal excretion17 This makes it potentially 
useful in patients with compromised hepatic function, but 
there is no research evidence to examine this issue.
Overall, amisulpride’s pharmacodynamic and pharma-
cokinetic properties indicate potential usefulness in a variety 
of clinical scenarios.
Amisulpride for positive symptoms
It is well established that amisulpride is at least as effective 
in the control of positive symptoms as conventional 
antipsychotic drugs.18 Indeed were this not the case, 
amisulpride would not have been authorized for the market. 
Moreover, amisulpride is at least as effective for the control of 
positive symptoms as some other atypical drugs;19,20 but is less 
likely to induce extrapyramidal side effects.21 For instance 
one study22 examined whether D1 receptor antagonism was 
necessary to treat positive symptoms, using a double blind 
randomized comparison of amisulpride with flupenthixol. 
Amisulpride was as least as effective, and better tolerated. 
This has been demonstrated repeatedly in patients in acute 
relapse.23
There are suggestions that amisulpride acts more rapidly 
than other drugs in acute relapse, when a predominance of 
positive symptoms would be expected.24 Indeed, it has more 
recently been shown in a large study of pooled data that there 
is more overall and positive symptom improvement in the 
first 2 weeks of treatment with amisulpride than in the second Neuropsychiatric Disease and Treatment 2009:5 269
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Table 1 Classification of negative symptoms
Symptom type Cause Result
Primary Pathophysiology of schizophrenia: failure to respond Poverty of ideation; poverty of affect
Consequences of primary symptoms Loss of motivation; poverty  
of speech; poverty of behavior;  
loss of self-care
Secondary negative Parkinsonism; unresolved positive symptoms; 
depression; oversedation; institutional environment; 
schizoid premorbid personality
Any of the above, plus additional 
symptoms specific to the cause  
of secondary symptoms
2 weeks, moreover, 68% of the improvement took place in 
the first 4 weeks of treatment.25 There is a similar finding in a 
small study of delusional disorder: amisulpride was effective 
within 2 weeks, continued to be effective at 3 months, and 
was well tolerated.26
Most of the evidence, then, regarding amisulpride in 
positive symptomatology points in the same direction, that 
amisulpride is efficacious and effective.
Amisulpride for negative symptoms
The negative syndrome implies an inability to respond to 
stimuli, whether these are internally or externally generated. 
Thus there is a lack, a ‘poverty,’ of normal mental activity 
and its consequences. This is most noticeable in ideation 
(thought) and emotional response (affect). It seems likely 
that the other hallmarks of the negative syndrome, such as 
poor social function, are secondary to these basic deficits. 
Unfortunately the term ‘secondary negative symptoms’ has 
been used to describe similar but unrelated presentations 
such as depression, Parkinsonism and ‘neuroleptic induced 
dysphoria,’ which may mimic the negative syndrome to the 
untrained observer (see Table 1). It is therefore very impor-
tant in any study of negative symptoms to establish that what 
is being rated is genuinely negative symptoms, rather than 
the alternatives.
Amisulpride displays some beneficial effects in animal 
models of negative symptoms.27 These include increasing 
regional glucose utilization, a proxy for neuronal activity, in 
the rat equivalent of human brain areas involved in cognition, 
motivation and emotion.28
In the clinical arena, amisulpride in low doses (100 mg per 
day) was compared with placebo, double blind, in a large 
randomized trial29 which met criteria for valid evaluation.30 
Patients had high levels of negative symptoms, and a 
DSM-III-R diagnosis of residual schizophrenia. There 
were substantial decreases in negative symptoms, about 
a third, in the amisulpride group: EPS were at placebo 
level. Positive, depressive and general symptoms were 
also significantly reduced, but the absolute changes were 
far less in percentage terms. Dropout rates were 20% for 
active treatment and 40% for placebo. It is difficult to find 
serious fault with this study or its findings, except to say 
that an active (conventional) comparator, had it produced an 
efficacy equivalent to placebo, would have made arguments 
for switching ‘deficit’ patients to low-dose amisulpride very 
hard indeed to refute.
Other studies of similar patients, although methodologi-
cally not as strong, have reported comparable findings.31–33
Even in acute exacerbation, when positive symptoms 
may predominate, and at high doses, amisulpride reduced 
negative symptoms more than haloperidol.34 However the 
dose of haloperidol utilized was relatively high at 20 mg 
per day in this study. This criticism could not be leveled at a 
similar study, which compared amisulpride in acute relapse 
with moderately high (8 mg daily) doses of risperidone.35 
Again, amisulpride was superior for negative symptoms. 
Nevertheless it is difficult to be sure that apparent negative 
symptoms were not secondary to positive symptoms, for 
instance leading to active social withdrawal easily interpreted 
as unresponsiveness.
An open but randomized study of 60 long stay chronic 
inpatients36 demonstrated only a trend toward better 
improvement in negative symptoms on amisulpride versus 
haloperidol over 1 year. Nonetheless, amisulpride was better 
tolerated in terms of the need for antimuscarinic medication. 
It is likely that these patients were quite treatment resistant 
and that there was very limited room for improvement on 
either medication. A similar, later study37 demonstrated 
a small but significant benefit in negative symptoms for 
amisulpride versus haloperidol in chronic or subchronic 
patients over 1 year.
A meta-analysis of 18 randomized controlled trials 
(RCTs)38 concluded that the supposed superiority of 
amisulpride for negative symptoms was genuine. The authors Neuropsychiatric Disease and Treatment 2009:5 270
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commented that this cast doubts on the requirement for 
serotonin 5HT2A antagonism as a mechanism conferring 
atypicality, not only in terms of negative symptom relief, 
but also regarding any reduced incidence of extrapyramidal 
side effects.
One neuroimaging study observed that frontal blood 
flow alterations occurred as expected in negative syndrome 
patients treated with low dose amisulpride, but clinical 
improvement was greatest in the patients whose negative 
symptoms were deemed secondary as opposed to primary.39 
Even so, a meta-analysis of four studies of patients with 
primary negative symptoms reported that there was an effect 
versus placebo on primary negative symptoms, although 
some improvements on placebo questioned the durability of 
primary negative symptoms over time.40 This is surprising 
since the clinical impression is that negative symptoms are 
usually stable and difficult to treat.
A recent trial of low dose amisulpride versus ziprasidone 
in patients with predominantly negative symptoms reported 
that the drugs were equivalent.41 A large randomized placebo 
controlled comparator trial versus olanzapine also found the 
two drugs to be equivalent: the authors commented that relief 
from extrapyramidal symptoms and positive symptoms was 
unlikely to be a valid explanation, but antidepressant effects 
may have contributed.42
Overall, then, there is good evidence for the efficacy 
of low dose amisulpride in negative symptomatology, 
even though there may be some contamination of the 
improvements in terms of relief from depression and extrapy-
ramidal side effects.
Amisulpride in depression
It is well established that dopamine antagonism may be 
associated with low mood and depressive symptoms, eg.43 
There are particular arguments for the relevance of dopamin-
ergic deficit in dysthymia.44 Regarding amisulpride, however, 
at low doses it exerts affinity for dopaminergic autorecep-
tors, thereby increasing rather than reducing dopaminergic 
output.11 Low doses potentiate prohedonic responses in rat 
models27 and amisulpride is active in other animal models 
of depression.45
There is good evidence that amisulpride is effective 
in dysthymia or chronic mild depression in low doses;46–54 
Indeed, amisulpride treatment in dysthymia is now so well 
established that it has been used as a reference drug in a 
comparator controlled trial.55
Low dose amisulpride may also be effective in major 
depression;56–58 and in partially responding patients with 
dysthymia or major depression, versus fluoxetine.59 There 
is no pharmacokinetic interaction with lithium.60
Regarding whether these promising actions translate 
into efficacy for depressive symptoms in schizophrenia, a 
very common clinical problem (which frequently responds 
poorly to antidepressants) there are some suggestions that 
they do. Effects include observed reductions in suicidal 
behavior, although controlled studies are lacking.61 Later 
work62 examined three studies which addressed depressive 
symptoms in acute exacerbation of schizophrenia treated with 
amisulpride, risperidone or haloperidol. Amisulpride was 
significantly superior to the other two drugs: the effect was 
enhanced in more severely depressed patients, and improve-
ments were seen from the second week of treatment. There 
is one double blind randomized 8 week comparison against 
olanzapine in schizophrenia patients with co-morbid depres-
sive episode, which demonstrated equivalence: however, the 
doses of amisulpride utilized were not low.63 Furthermore, 
olanzapine was associated with significant unwanted effects 
on weight and metabolism.
Amisulpride was compared with continuation of risperi-
done in a recent randomized open study of depressed patients 
with schizophrenia: amisulpride proved superior compared 
to ongoing risperidone treatment for depressive symptoms, 
although the doses used, again, were not low.64
In summary, there seems little doubt that amisulpride is 
efficacious in a variety of depressive disorders: the evidence 
in depressive symptomatology integral to schizophrenia is 
less solid, but even so indicates that a trial of amisulpride 
can be recommended in those circumstances.
Amisulpride in first episode 
schizophrenia
Amisulpride compared to usual treatment reduced positive 
and negative symptoms and improved global function in 
a late prodromal or early psychotic group of patients.65 
Amisulpride was the treatment of choice for late prodromal 
patients in a randomized German study:66 treatment mark-
edly enhanced the benefits of psychosocial interventions.67 
There is one small study of amisulpride in first episode 
patients which demonstrated that after 6 months the 
negative symptoms and quality of life of the patients had 
improved.68
The European First-Episode Schizophrenia Trial 
(EUFEST)69 randomized 500 first episode patients in 
14 countries to haloperidol or atypical antipsychotic treat-
ment: amisulpride, quetiapine, olanzapine or ziprasidone. 
Despite a high discontinuation rate with haloperidol, Neuropsychiatric Disease and Treatment 2009:5 271
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72% after one year, compared to significantly lower 
discontinuation of the other drugs (40%, 53%, 33% and 
45% respectively) the authors concluded that atypical 
drugs were not superior. Greater discontinuation with 
haloperidol was attributed to poor prescriber expectations 
of haloperidol, and this conclusion was substantiated by 
finding no difference between treatments in PANSS scores, 
although simpler scales did differ. EUFEST has generated 
much controversy.
The relatively limited evidence for the use of amisulpride 
in first episode patients makes it difficult to draw firm 
conclusions about its relative usefulness compared to other 
atypical or even conventional antipsychotic drugs, some 
of which may be better tolerated for instance regarding 
hyperprolactinemia. First episode schizophrenia is a clinical 
scenario where medication must very much be tailored to the 
individual patient. Nevertheless amisulpride would certainly 
not be ruled out from the range of first or second antipsy-
chotic choices.
Amisulpride in treatment resistance
There is one report of the utility of amisulpride monotherapy 
in treatment resistant schizophrenia.70
An early study71 suggested that amisulpride was a useful 
adjunct when clozapine side effects could not be tolerated: 
the addition of amisulpride enabled the dose of clozapine to 
be halved in one patient. This was followed by three small 
open studies with promising results in respect of relief of 
symptomatology and global improvement,72–74 and one 
double-blind placebo controlled study.75 It was demon-
strated that clozapine raised plasma levels of amisulpride, 
but whether this contributed to the effectiveness of the 
combination is not known.76
Regarding other atypical antipsychotic drugs, there is 
preliminary evidence that the combination of olanzapine and 
amisulpride may be effective77 and that other non-clozapine 
atypical antipsychotic combinations including amisulpride 
may be of value.78 Another small study observed that ami-
sulpride augmentation of several atypical drugs including 
clozapine was effective in most patients.79
A more recent review of a large number of studies80 
concluded, again, that amisulpride was one of a number 
of atypical antipsychotic drugs which could augment 
the actions of clozapine in treatment resistant patients. It 
has since been reported in a small study that combining 
amisulpride with clozapine enabled the dose of clozapine 
to be reduced by 13%, the combination was effective and 
there were no substantial tolerability issues.81 The value of 
the clozapine/amisulpride combination has continued to 
be replicated.82 One very small, double blind randomized 
placebo controlled study failed to find any symptomatic 
effect, but secondary, global efficacy measures and 
depressive symptoms improved. Nonetheless, amisulpride 
side effects were in evidence.83
A later randomized study compared quetiapine with 
amisulpride added to clozapine in partially responding 
patients over 8 weeks. Both drugs were associated with an 
improvement but the degree was superior on amisulpride.84 
Finally, the addition of amisulpride to clozapine has a useful 
antihypersalivation effect;85,86
As a whole, there is more evidence for the utility of 
amisulpride as an adjunct to clozapine than for any other 
antipsychotic drug, or indeed for any other augmentation 
with other drug classes.
Amisulpride and cognition
Cognitive impairment is ubiquitous in schizophrenia: there 
has been much interest in antipsychotic drugs as potential 
cognitive enhancers or detractors over the years. Amisulpride 
did not enhance alcohol induced cognitive impairment in 
healthy volunteers87 neither did it enhance the effects of sleep 
deprivation.88 Compared to haloperidol, again in volunteers, 
amisulpride did not disrupt cognitive skill learning on motor 
and executive tasks, like haloperidol there was cognitive 
slowing but to a much more minor degree.89 Amisulpride 
in a single dose up to 200 mg did not impair performance 
on a battery of cognitive tests in young males, neither did 
it affect the impairment induced by lorazepam when both 
were given.90 In a 5-day trial of amisulpride versus a low 
dose of haloperidol, 4 mg daily in healthy volunteers, ami-
sulpride failed to disrupt cognition significantly at all until 
the last day at the 400 mg dose: substantially greater effects 
of haloperidol were apparent throughout.91 In a small study 
of healthy elderly volunteers, amisulpride actually enhanced 
cognitive performance compared to placebo: again, haloperi-
dol impaired performance.92
A review of 19 studies of amisulpride which included 
cognitive tests concluded that there were no effects up to 
400 mg daily and only mild effects at higher doses.93 The 
alerting effects at low doses as observed on EEG record-
ings were emphasized. However, amisulpride does abolish 
the enhancement of memory in the context of emotionally 
aversive or arousing stimuli.94 Furthermore, in inpatients 
with schizophrenia, although amisulpride like other atypical 
antipsychotic drugs induced less psychomotor slowing 
than conventional drugs (possibly attributable to milder Neuropsychiatric Disease and Treatment 2009:5 272
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extrapyramidal effects) it failed to distinguish itself from 
other atypical and conventional drugs in standard non-
motor neuropsychological tests.95 One small switching study 
observed improved memory performance on amisulpride in 
patients previously treated with risperidone.96
As opposed to compromise of cognition, there is the 
question of whether amisulpride in low doses acts as a 
cognitive enhancer in schizophrenic patients. One small 
neuro-imaging study of patients with the negative syndrome 
suggested that it did.69,83 Another long term study of cognition 
in patients taking atypical antipsychotic drugs reported 
that patients treated with those which antagonized 5HT2A 
receptors experienced compromise, while those taking drugs 
which did not (amisulpride and quetiapine) had enhanced 
aspects of memory and executive function.97 This was partly 
replicated98 in a comparison of amisulpride and olanzapine: 
patients’ cognition improved on both drugs, thus detracting 
from the notion that 5HT2A antagonism was a necessary 
prerequisite for antipsychotic drug induced enhancement 
of cognition in schizophrenia. A more recent randomized 
6-month trial of acute patients again demonstrated cognitive 
improvements on both olanzapine and amisulpride99 but 
there was a particular advantage for amisulpride in a verbal 
memory test.
It is difficult to make clinical sense of these studies 
overall. Essentially it is important to spare cognition when 
treating psychosis, and amisulpride does appear to pass this 
test. However, the functional or adaptive effects of small 
changes in neuropsychological task performance are unlikely 
to be of pronounced relevance to most patients.
Amisulpride and adaptive function
There is one study demonstrating sustained improvement on a 
measure of social function during amisulpride treatment.100 
A double-blind 4-month RCT using haloperidol as a 
comparator found that amisulpride was associated with 
improved quality of life and functional status.101 Further work 
concurred that amisulpride is significantly more effective 
than haloperidol and placebo in a number of social function 
and quality of life measures.102 A naturalistic mirror image 
study over a year demonstrated improvements in global 
function, quality of life and service uptake, rendering ami-
sulpride more cost-effective than previous treatment.103 
Compared with antipsychotic drugs with strong serotonin 
5HT2A affinity, patients treated with amisulpride improved 
their social function in the long term.104
A large study of subjective well-being105 reported that 
amisulpride treatment was effective in improving patients’ 
well-being, but much of the response was attributable to the 
resolution of poorly controlled positive symptoms.
Essentially this work reiterates that the results of effective 
antipsychotic drug therapy go beyond simple symptom 
reduction and control, but extend to adaptive functionality: 
it is not clear whether amisulpride is superior to other 
antipsychotic drugs in this regard, with the possible exception 
of haloperidol.
Discussion: differential indications 
for amisulpride?
The first clear statement to appear in the literature, to the 
effect that the advantages of atypical antipsychotic drugs 
over the conventional variety did not imply differential 
indications (with the exception of clozapine for treatment 
resistance) appeared in 2000.106 This was rapidly followed 
by a meta-analysis which argued that any advantages of 
atypical antipsychotic drugs, including amisulpride, were 
attributable to excessive doses of the conventional com-
parator, particularly when it was haloperidol. The authors 
recommended that atypical drugs should not be used unless 
the patient was intolerant of the side effects of lower doses of 
conventional antipsychotic drugs.107 This was on acquisition 
cost grounds. The work was widely criticized at the time, and 
was not translated into UK Government guidance regarding 
the drug treatment of schizophrenia 2 years later.108 Even so, 
later work concurred that the use of higher than recommended 
doses of haloperidol in comparator trials had taken place, and 
had hampered the interpretation of the results.109
It continued to be argued that amisulpride and other 
atypical antipsychotic drugs did possess genuine advantages 
over conventional antipsychotic drugs, particularly 
regarding tolerability.110 Amisulpride was suggested as 
a singularly good option when the antipsychotic drug 
needed to be changed, owing to its efficacy for negative and 
affective symptoms and its lack of redundant affinities111 or 
owing to its predecessor’s lack of efficacy and tolerability 
in general.112 Indeed, a study which examined a variety 
of patients whose treatment was switched to amisulpride 
reported that the change was not problematic.113 More recent 
work has demonstrated advantages for risperidone treated 
patients switched to amisulpride96 including better memory 
performance.
Despite these encouraging findings, a large naturalistic 
study of outpatients has reported that amisulpride treated 
patients were less likely to remain on their treatment 
than patients treated with olanzapine114 and this has been 
replicated.115 In contrast a study of patients switched to Neuropsychiatric Disease and Treatment 2009:5 273
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amisulpride from conventional treatment observed an almost 
doubling of compliance rates.116
Nevertheless, the claimed rapid onset of action of 
amisulpride has made it a good choice for first-line 
treatment;24,117 while its versatility in terms of positive, 
negative, affective and cognitive symptoms coupled with 
its tolerability suited it to chronic treatment as well;118,119 
Furthermore, four meta-analyses have now concluded that 
amisulpride is globally superior to conventional treatment 
and placebo across symptom profiles;38,120–122
Other work has supported this, in long term studies of 
patients with mixed positive and negative symptoms.123 
A subsequent prospective appraisal of the effects of amisul-
pride on five different symptom dimensions concluded that 
it was effective for all.124
Therefore, amisulpride has been recommended as 
appropriate in most clinical scenarios for the treatment 
of schizophrenia,125 not just at low doses for patients 
with predominantly negative symptoms. Amisulpride is 
well tolerated compared to both conventional and other 
atypical antipsychotic drugs.126 Higher dosage ranges may 
be used without difficulty127 particularly in more severely 
ill patients.128 Nevertheless, most symptom dimensions in 
the BPRS including depression/anxiety and anhedonia/
negative symptoms will respond within the dose range of 
400 to 800 mg.129
In comparison with other individual atypical antipsy-
chotic drugs, there is evidence of overall superiority of 
symptom relief compared to risperidone in chronic patients130 
although a similar study found no differences.131 Amisulpride 
appears equivalent to olanzapine in acute patients132 and in 
stable patients on a variety of outcome measures.133
Of two recent reviews, one concluded that it was 
difficult to distinguish atypical antipsychotic drugs in terms 
of efficacy134 while the other concluded that there were 
significant differences in both efficacy and tolerability.135 
Nevertheless, amisulpride may offer advantages over other 
atypical antipsychotic drugs in the treatment of negative and 
depressive symptoms, and tolerability advantages such as the 
avoidance of weight gain.136
Unfortunately, the findings of the CATIE (Clinical 
Antipsychotic Trials for Intervention Effectiveness) schizo-
phrenia trial published over the last 2 or 3 years have cast 
considerable doubt on the validity of differences between 
atypical and conventional antipsychotic drugs, both on a 
group and individual basis. As a North American study, 
CATIE did not include amisulpride, but there is little 
obvious reason to suspect that the inclusion of amisulpride 
would have substantially altered the findings. CATIE 
randomized an ordinary clinical sample of 1460 outpatients 
eligible for a change in medication: time to discontinua-
tion was the primary outcome variable in terms of efficacy. 
Patients commenced one of four atypical antipsychotic 
drugs or perphenazine, a conventional antipsychotic drug, 
for 18 months. The ‘take home messages’ of CATIE were 
firstly that the atypical drugs demonstrated no efficacy or 
tolerability advantages over perphenazine, and secondly 
that 75% of the patients had discontinued the medication 
to which they had been randomized by the end. Objections 
to the validity and interpretation of the results are pos-
sible, but perhaps represent no more than ‘starting points 
for sharpening debate and focusing efforts better in the 
future’:137 in other words, the findings do stand up to scru-
tiny. The CUtLASS study in the UK, which implemented 
a broadly similar design, included amisulpride: CUtLASS 
reported similar findings to CATIE, and came to similar 
conclusions.138,139
The inevitable return to the argument that all antipsy-
chotic drugs (except clozapine) are the same may be rebut-
ted, nonetheless, by the contention that although this may 
be true for groups of patients, there is much inter-individual 
variability, particularly in the atypical group, in respect of 
side effects and possibly efficacy to some degree too. This is 
because what can be deduced from the high discontinuation 
rates in such trials as CATIE and CUtLASS is that no single 
medication suits all patients. In other words similarity of 
outcome applies to groups of patients, not to the individual 
patient: there remains the need for a high degree of skill 
and experience in choosing antipsychotic treatment for each 
person who needs it.
Conclusions
Amisulpride is an atypical antipsychotic drug with a unique 
mechanism of action. It differs from every other antipsychotic 
drug in that it is indicated for dysthymia: there is reasonably 
consistent evidence that amisulpride is useful in depressive 
symptoms and negative symptoms in schizophrenia, particu-
larly at low doses. Amisulpride presents the best evidence 
for utility as an adjunct to clozapine in treatment resistant 
schizophrenia. These advantages compared to other antip-
sychotic drugs do not, however, preclude amisulpride from 
general use: it is effective in patients with positive symptoms, 
functional and cognitive compromise, in acute and long term 
clinical scenarios, first episode and relapse. Amisulpride is 
therefore a rational choice, both in general and in particular, 
for the treatment of patients with schizophrenia.Neuropsychiatric Disease and Treatment 2009:5 274
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